Momat Rhino Advance nasal spray 140mcg+50mcg/dose, 150 dose bottle

Composition

Nasal spray

Active ingredients:

 azelastine hydrochloride-140 mcg,

mometasone furoate-50 mcg. Auxiliary substances:

cellulose microcrystalline (Avicel RC-591) – 0,910 mg,

sodium carmellose -0,021 mg,

dextrose – 3,500 mg,

Polysorbate-80 – 0,0175 mg,

benzalkonium chloride 0,014 mg,

disodium edetate – 0,035 mg,

neotame – 0,0007 mg,

citric acid monohydrate – 0,0105 mg,

sodium citrate – 0,021 mg,

purified water – up to 70 mg.

Pharmacological action

Combined anti-allergic agent (H1-histamine receptor blocker+topical corticosteroids).

Indications

Rhinitis

Contraindications

Hypersensitivity to the components of the drug

Side effects

Often: headache, dysgeusia (unpleasant taste) as a consequence of improper use, namely, when the head is excessively tilted back during use. Very rare:  dizziness (may be caused by the disease itself). Disorders of the gastrointestinal tract: Rarely: sensation of irritation of the pharyngeal mucosa, nausea. Respiratory, thoracic and mediastinal disorders:  

Often: nosebleeds, discomfort in the nasal cavity (burning sensation, itching), ulceration of the nasal mucosa, sneezing, pharyngitis, sinusitis, upper respiratory tract infections. Immune system disorders: Very rare: hypersensitivity, anaphylactoid reactions. Skin and subcutaneous tissue disorders: Very rare: rash, pruritus, urticaria. General disorder and disorders at the injection site: Very rare: fatigue, drowsiness, weakness (may be caused by the disease itself). Long-term use of high-dose glucocorticosteroids (corticosteroids) may cause systemic side effects, including glaucoma and cataracts.

Interaction

Azelastine. Ingranasal use of azelastip did not reveal a clinically significant interaction with other drugs. Mometasone furoate. Combination therapy with loratadine was well tolerated by patients.

However, there was no effect of the drug on the concentration of loratadine or its main metabolite in blood plasma. In these studies, mometasone furoate was not detected in blood plasma (with the sensitivity of the determination method of 50 pg / ml).

How to take, course of use and dosage

Iitranasal.

The suspension contained in the bottle is inhaled using a special dosing nozzle on the bottle.

1 dose of spray (azelastine hydrochloride-140 mcg / momstazone furoate-50 mcg) in each nostril 2 times a day in the morning and evening.

The duration of treatment is 2 weeks.

Overdose

Currently, cases of overdose of the drug with ingranasal use are unknown. In case of overdose of azelastine as a result of accidental ingestion, there may be disorders of the nervous system (drowsiness, confusion. tachycardia, hypotension). Treatment of these disorders is symptomatic.

With prolonged use of high-dose glucocorticosteroids, as well as with the simultaneous use of several corticosteroids, it is possible to inhibit the hypothalamic-pituitary-adrenal system.

Due to the low systemic bioavailability of the drug, it is unlikely that accidental or intentional overdose will require any measures other than monitoring, with possible subsequent resumption of the drug at the recommended dose.

Special instructions

As with any long-term treatment, patients who have been using Momat Reno Advance nasal spray for several months or longer should be periodically checked by a doctor for possible changes in the nasal mucosa, perforation of the nasal septum (very rarely) and possible development of systemic side effects.

If a local fungal infection of the nose or pharynx develops, it may be necessary to stop therapy with Momat Reno Advance nasal spray and conduct special treatment. In case of persistent nasopharyngeal irritation, it is necessary to decide whether to stop therapy.

Patients who switch to treatment with Momat Reno Advance nasal spray after long-term therapy with systemic glucocorticosteroids require special attention. Withdrawal of systemic glucocorticosteroids in such patients may lead to insufficient adrenal function, the subsequent recovery of which may take up to several months. If signs of adrenal insufficiency appear, you should resume taking systemic glucocorticosteroids and take other necessary measures.

During the transition from systemic glucocorticosteroid treatment to Momat Reno Advance nasal spray treatment, some patients may experience initial symptoms of withdrawal of systemic glucocorticosteroids (for example, joint and/or muscle pain, fatigue, and depression), despite a decrease in the severity of symptoms associated with damage to the nasal mucosa; such patients should be specifically persuaded to continue treatment with Momat Reno Advance nasal spray.

Switching from systemic to local glucocorticosteroids may also reveal pre-existing allergic diseases, such as allergic conjunctivitis and eczema, but masked by systemic glucocorticoid therapy.

When using intranasal steroids at doses higher than recommended, or in sensitive patients at recommended doses, systemic effects of glucocorticosteroids and adrenal suppression may develop. If such changes occur, the use of Momat Reno Advance nasal spray should be gradually discontinued, in accordance with the procedures adopted for discontinuing oral glucocorticosteroids.

Patients treated with glucocorticosteroids have potentially reduced immune reactivity and should be warned about their increased risk of infection if they come into contact with patients with certain infectious diseases (for example, chickenpox, measles), as well as about the need for medical advice if such contact has occurred.

If there are signs of a severe bacterial infection (for example, fever, persistent and sharp pain on one side of the face or toothache, swelling in the orbital or periorbital area), immediate medical advice is required. Glucocorticosteroids for nasal and inhaled use can cause the development of glaucoma and / or cataracts. Therefore, patients with visual changes should be closely monitored, as well as patients who have previously experienced increased intraocular pressure, glaucoma and / or cataracts.

Effects on the ability to drive vehicles and engage in other activitiesin rare cases, fatigue, tiredness, dizziness and weakness, which may be a consequence of the disease itself, can develop when using Momat Reno Advance nasal spray. In such cases, you should avoid driving a vehicle and working with complex mechanisms.

Shelf life

2 years

Active ingredient

Azelastine, Mometasone

Dosage form

nasal spray

Description

For adults as directed by your doctor

Indications

Allergy, Allergic rhinitis